Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Overview
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Companies Involved in Therapeutics Development
Alteogen Inc
Amgen Inc
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Cingen Co
Clover Biopharmaceuticals
Coherus BioSciences Inc
Formycon AG
Gene Techno Science Co Ltd
Huons Global Co Ltd
i2 Pharmaceuticals Inc
Lupin Ltd
Luye Pharma Group Ltd
Momenta Pharmaceuticals Inc
PharmAbcine Inc
Regeneron Pharmaceuticals Inc
Samsung Bioepis Co Ltd
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Drug Profiles
aflibercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
aflibercept SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
conbercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KH-906 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-186 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SL-188 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ziv-aflibercept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ziv-aflibercept biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Dormant Products
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Discontinued Products
Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Product Development Milestones
Featured News & Press Releases
Apr 08, 2020: Bayer launches pre-filled syringe to administer eye medication Eylea in Europe
Feb 10, 2020: Bayer announces Phase III trials with new aflibercept 8mg formulation
Feb 10, 2020: Regeneron reports two-year diabetic retinopathy data of Eylea
Jan 23, 2020: Bayer submits application to European Medicines Agency for pre-filled syringe to administer eye medication Eylea
Aug 13, 2019: Last trial OKed for Eylea to prevent blindness in premature infants
Aug 13, 2019: FDA approves Eylea (AFLIBERCEPT) prefilled syringe
Jun 21, 2019: Bayer initiates phase III trial of Aflibercept to prevent blindness in premature infants
May 22, 2019: Alteogen obtained IND approval for a clinical trial in Korea for Eylea Biosimilar (ALT-L9)
May 13, 2019: Formycon provides update on FYB203
May 13, 2019: FDA Approves EYLEA (aflibercept) Injection for Diabetic Retinopathy
Apr 30, 2019: Watchful waiting reasoble for patients with Diabetic Macular Edema and good vision
Apr 02, 2019: LY09004 approved for clinical trials in Chi, Luye Pharma steps-up Global R&D Investment in Biopharma Medicines
Feb 28, 2019: Alteogen applies for P1 trial for Eylea biosimilar
Feb 09, 2019: One-year results from positive phase 3 EYLEA trial in diabetic retinopathy presented at Angiogenesis Symposium
Jan 21, 2019: New anti-VEGF agent shows promising durability
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Mechanism of Actions, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Routes of Administration, H1 2020
Number of Products by Stage and Routes of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020


List of Tables


Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Products under Development by Companies, H1 2020 (Contd..2), H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Alteogen Inc, H1 2020
Pipeline by Amgen Inc, H1 2020
Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, H1 2020
Pipeline by Cinnagen Co, H1 2020
Pipeline by Clover Biopharmaceuticals, H1 2020
Pipeline by Coherus BioSciences Inc, H1 2020
Pipeline by Formycon AG, H1 2020
Pipeline by Gene Techno Science Co Ltd, H1 2020
Pipeline by Huons Global Co Ltd, H1 2020
Pipeline by i2 Pharmaceuticals Inc, H1 2020
Pipeline by Lupin Ltd, H1 2020
Pipeline by Luye Pharma Group Ltd, H1 2020
Pipeline by Momenta Pharmaceuticals Inc, H1 2020
Pipeline by PharmAbcine Inc, H1 2020
Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
Pipeline by Samsung Bioepis Co Ltd, H1 2020
Dormant Projects, H1 2020
Discontinued Products, H1 2020